SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Lyra Therapeutics, Inc. (LYRA) .
Criteria proven by this page:
- VALUE (60/100, Pass) — analyst target implies upside (+13.6%).
- Analyst consensus target $0.50 (+13.6% upside) — modest upside expected.
Overall SharesGrow Score: 34/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LYRA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio17.18
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-18.62
Book Value / Share$0.00
Revenue / Share$0.03
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$0.50 (+13.6%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.98 |
$1.24M |
$-6.03M |
-484.6% |
| 2019 |
$-62.50 |
$0.00 |
$-16.09M |
- |
| 2020 |
$-2.59 |
$0.00 |
$-22.05M |
- |
| 2021 |
$-3.35 |
$285K |
$-42.41M |
-14880.7% |
| 2022 |
$-1.83 |
$1.36M |
$-55.28M |
-4055.6% |
| 2023 |
$-1.26 |
$1.56M |
$-62.68M |
-4023.1% |
| 2024 |
$0.00 |
$1.53M |
$-93.44M |
-6090.9% |
| 2025 |
$-18.62 |
$398K |
$-28.92M |
-7266.1% |
